Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.62 |
| ▸ | MET | P08581 | 1/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.58 |
| ▸ | STK3 | Q13188 | 2/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.58 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.58 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.58 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.58 |
| ▸ | PRKCG | P05129 | 1/20 | 0.58 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | AKT1 | P31749 | 1/20 | 0.58 |
| ▸ | AKT2 | P31751 | 1/20 | 0.58 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.58 |
| ▸ | PRKCI | P41743 | 1/20 | 0.58 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.58 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17040585 | 0.83 | ROCK2 (0.75) | ROCK2PRKD3METROCK1CSNK2A1 | |
| SCHEMBL882785 | 0.82 | ROCK2 (0.74) | ROCK2PRKD3METROCK1CSNK2A1 | |
| SCHEMBL17040605 | 0.82 | ROCK2 (0.70) | ROCK2PRKD3METROCK1 | |
| SCHEMBL19591997 | 0.81 | ROCK2 (0.44) | ROCK2PRKD3METROCK1CSNK2A1 | |
| SCHEMBL10220857 | 0.80 | PRKD3 (0.76) | ROCK2PRKD3METROCK1CSNK2A1 | |
| SCHEMBL17040576 | 0.80 | ROCK2 (1.00) | ROCK2ROCK1CSNK2A1STK3AURKB | |
| SCHEMBL17040581 | 0.80 | ROCK2 (0.87) | ROCK2ROCK1CSNK2A1STK3AURKB | |
| SCHEMBL10218675 | 0.79 | ROCK2 (0.82) | ROCK2ROCK1CSNK2A1STK3AURKB | |
| SCHEMBL24271400 | 0.79 | ROCK2 (0.62) | ROCK2ROCK1CSNK2A1STK3AURKB | |
| SCHEMBL882941 | 0.79 | ROCK2 (0.69) | ROCK2PRKD3METROCK1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210147391-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION LLC | 2021-05-20 | — | — | US | disclosed |
| US-10696660-B2 | Rho kinase inhibitors | KADMON CORPORATION, LLC (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190308953-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION LLC | 2019-10-10 | — | — | US | disclosed |
| US-10183931-B2 | Rho kinase inhibitors | KADMON CORPORATION, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170112832-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | KADMON CORPORATION, LLC | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696660-B2 | Rho kinase inhibitors | ROCK2, ROCK1, RHOA | ROCK2 1/4885PRKD3 166/4885MET 669/4885 |
| US-20170112832-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOA | ROCK2 1/4885PRKD3 775/4885MET 2117/4885 |
| US-10183931-B2 | Rho kinase inhibitors | ROCK2, ROCK1, RHOA | ROCK2 1/4885PRKD3 166/4885MET 669/4885 |
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | ROCK2, KDR, FLT1 | ROCK2 1/4885PRKD3 790/4885MET 182/4885 |
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | ROCK2 1/4885PRKD3 838/4885MET 1932/4885 |
| US-20190308953-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | ROCK2 1/4885PRKD3 166/4885MET 669/4885 |
| US-11311541-B2 | Treatment of GVHD | ROCK2, ROCK1, RHOA | ROCK2 1/4885PRKD3 775/4885MET 2117/4885 |
| US-20210147391-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | ROCK2 1/4885PRKD3 166/4885MET 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.